西妥昔单抗联合卡铂放疗用于不适合顺铂的局部晚期头颈鳞癌的前瞻性研究
这项单臂1/2期研究纳入60例既往未治疗、适合根治性治疗但不适合顺铂的局部晚期口咽、喉或下咽鳞癌患者,评估西妥昔单抗联合卡铂放疗方案的可行性。结果显示可行性为55/60(91.7%,90%CI 83.3%-96.7%),达到预设标准;4年局部区域控制率82%,无失败生存率72%,总生存率77%,严重晚期毒性很少。
要点
- 该方案在不适合顺铂的局部晚期头颈鳞癌患者中可行性达91.7%,满足预设标准。
- 4年局部区域控制率82%、无失败生存率72%、总生存率77%。
- ≤70岁与>70岁患者4年无失败生存率和总生存率无显著差异。
核心结论
- 西妥昔单抗联合卡铂放疗方案在不适合顺铂的局部晚期头颈鳞癌患者中可行且安全。
研究设计与样本
- 单臂1/2期研究,纳入60例既往未治疗、活检证实为口咽、喉或下咽鳞癌且适合根治性治疗但不适合顺铂的患者。
- 主要终点为方案可行性,即成功完成治疗的患者比例;次要终点包括局部区域控制、无失败生存、总生存和治疗毒性。
主要发现
- 患者平均年龄66岁(范围42-87岁),28%的患者>70岁,中位随访时间4年。
- 可行性为55/60(91.7%,90%CI 83.3%-96.7%),满足预设标准。
- 4年局部区域控制率为82%(95%CI 71-94),无失败生存率为72%(95%CI 60-85),总生存率为77%(95%CI 66-90)。
- 4年首次失败累积发生率:局部5.2%、局部加远处1.8%、区域8.5%、区域加远处1.7%、远处3.5%、任何原因死亡7.7%。
- ≤70岁与>70岁患者4年无失败生存率分别为71%(95%CI 58-88)和73%(95%CI 54-100)(log-rank P=.801),4年总生存率分别为79%(95%CI 66-93)和73%(95%CI 53-100)(log-rank P=.708)。
临床怎么用
- 对于不适合顺铂的局部晚期头颈鳞癌患者,可考虑西妥昔单抗联合卡铂放疗方案。
- 该方案在>70岁患者中同样可行,且与≤70岁患者生存无显著差异。
局限性
- 单臂研究设计,未设对照组。
- 样本量60例,随访4年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report on the outcomes of a novel treatment regimen for patients with locally advanced head and neck squamous cell carcinoma who were fit for curative treatment but not fit for cisplatin. METHODS AND MATERIALS: Single-arm phase 1/2 study of previously untreated patients with biopsy-proven SCC of the oropharynx, larynx, or hypopharynx. The primary endpoint was feasibility of the regimen, defined as the proportion of patients successfully completing treatment. Secondary endpoints were locoregional control (LRC), failure-free survival (FFS), overall survival (OS), and treatment toxicities. RESULTS: Sixty patients were included in the study. Their mean age was 66 years (range, 42-87 years); 28% of patients were >70 years. The median follow-up time was 4 years. Compliance with treatment was very high: feasibility was 55/60 (91.7%, 90% CI: 83.3%-96.7%), which satisfied the predefined criteria. The 4-year LRC was 82% (95% CI: 71-94), the FFS was 72% (95% CI: 60-85), and the OS was 77% (95% CI: 66-90). The cumulative incidences of first failure of any type at 4 years were 5.2% local, 1.8% local and distant, 8.5% regional, 1.7% regional and distant, 3.5% distant, and 7.7% death (any cause). The 4-year FFS in the patients aged ≤70 years and >70 years were 71% (95% CI: 58-88) and 73% (95% CI: 54-100), respectively (log-rank P=.801). Their 4-year OS was 79% (95% CI: 66-93) and 73% (95% CI: 53-100), respectively (log-rank P=.708). Significant late treatment toxicities were very few. CONCLUSION: This treatment regimen was feasible and safe in this patient cohort unfit for cisplatin, 28% of whom were older than 70 years. Carboplatin-based and cetuximab-based chemoradiation regimens warrant further investigation in patients with a contraindication to cisplatin.
引用
- Corry J, Bressel M, Fua T, et al. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. Int J Radiat Oncol Biol Phys. 2017. PMID: 28483336. doi:10.1016/j.ijrobp.2017.02.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。